Table 3.
AMP cytotoxicity and hemolytic activity.
IC50 (μg/mL) | HC50 (μg/mL) | ||
---|---|---|---|
Peptide sequence | Peptide code | HEK-293a | Human red blood cells |
GLFDVIKKVASVIGGL | AMP-001/Cit 1.1 | 20.98 | > 32 |
GLFDVI(Orn)(Orn)VASVIGGL | AMP-006 | > 32 | > 32 |
GLFDVIRRVASVIGGL | AMP-012 | 17.64 | 18.2 |
GLFDVIRKVASVIGGL | AMP-013 | 21.26 | > 32 |
GLFEVIKKVASVIGGL | AMP-015 | > 32 | > 32 |
GLWDVIKKVASVIGGL | AMP-016 | > 32 | 16.85 |
GLWRVIRKVASVIGGL | AMP-017 | 18.10 | 26.7 |
PhenylGlyLWDVIRKVASVIGGL | AMP-018 | 19.44 | > 32 |
GL(Biphenylalanine)DVIKKVASVIGGL | AMP-019 | 17.04 | > 32 |
GL(1-Nap)DVIKKVASVIGGL | AMP-020 | 16.85 | > 32 |
SarLWDVIRKVASVIGGL | AMP-021 | 30.90 | > 32 |
Human embryonic kidney cells (ATCC CRL-1573). Assays were performed by The Community for Antimicrobial Drug Discovery (CO-ADD), Australia.